CURE SYNGAP1 has announced a $130,000 grant to Dr. Helen Willsey and Dr. David Kastner at the University of California, San Francisco (UCSF) to further investigate the role of SYNGAP1 in cilia formation and its implications for brain anatomy and behavior. This funding will enable research into how deficiencies in the SYNGAP1 protein contribute to various symptoms associated with SYNGAP1-Related Disorders (SRD), including intellectual disabilities and behavioral issues. Utilizing rodent models, the team will explore the connection between SYNGAP1 protein dysfunction and clinical manifestations in patients. Dr. Willsey's previous research has highlighted the importance of SYNGAP1 beyond synaptic functions, indicating its involvement in broader systemic roles. The findings from this study aim to inform drug design and improve treatment strategies for affected individuals. Dr. Willsey expressed gratitude for the support from CURE SYNGAP1, emphasizing the potential for this research to lead to targeted therapies that enhance patient outcomes. The collaboration is expected to significantly impact the understanding and treatment of SYNGAP1-related conditions.